Validation of the European Oncology Quality of Life Toolkit

July 17, 2023 updated by: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Validation of the European Oncology Quality of Life Toolkit. A European Pilot Survey.

The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PROMs) for QoL assessment in routine oncology practice has positive effects on patient wellbeing and healthcare resource utilization. However, full implementation of PROMs is not yet part of standard of care and is not adequately considered in cancer policies and programs.

A comprehensive tool incorporating the perspective of patients at different stages of the disease trajectory and widely applicable across Europe is still lacking.

The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL, developed from preferences and priorities of people with past or current cancer experience. The EUonQoL-Kit includes three electronic questionnaires, specifically designed for different disease phases (patients in active treatment, survivors, and patients in palliative care), available in both static and dynamic (Computer Adaptive Testing, CAT) versions and in several European languages.

This is a multicentre observational study, with the following aims:

  • The primary aim is to perform the psychometric validation of the EUonQoL-Kit.
  • Secondary aims are to assess its acceptability, to validate the CAT version, and to provide estimates of QoL across different European countries.

The EUonQoL-Kit will be administered to a sample of cancer patients and survivors from 46 European cancer centres. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C).

Each centre will recruit 100 patients (40 from group A, 30 from group B, 30 from group C), for an overall sample size of 4,600 patients (at least 4,000 patients are assumed to be enrolled, due to an expected lower recruitment rate of 10-15%). Three sub-samples of patients (each corresponding to 10% of the total sample for each centre) will fill in an additional questionnaire:

  • EORTC QLQ-C30, to test concurrent validity.
  • Live-CAT version, to test the feasibility of such implementation.
  • EUonQoL-Kit, 2-7 days after the first completion, to assess test-retest reliability.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Several patient-reported questionnaires have been developed and validated to measure quality of life (QoL) of cancer patients. However, a comprehensive tool, developed in close collaboration with people who have experienced cancer, widely applicable across Europe and tailored to the health status of the individual patient, is lacking. Such a tool will be important for incorporating the patient's perspective into the evaluation of policies and programs addressing cancer at the European level.

The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL based on preferences of cancer patients and survivors. It is developed from a patient perspective, administered digitally, available in the languages of the European Union (EU) 27 and several associated countries, and applicable in future surveys to contribute to the EU's mission on cancer. It includes three static questionnaires specifically developed for different disease phases (patients in active treatment, survivors, and patients in palliative care), and three dynamic versions of the same questionnaires based on Item Response Theory (IRT) and Computer Adaptive Testing (CAT).

This is an observational study aimed to perform the psychometric validation of the EUonQoL-Kit through its first large scale application in a pan European pilot survey.

The EUonQoL-Kit will be tested in a sample of cancer patients and survivors from 46 oncological centres located in 33 European countries. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C). Each centre will recruit a sample of 100 participants (40 from group A, 30 from group B, 30 from group C), stratified for primary diagnosis: lung cancer, breast cancer, colorectal cancer, haematological malignancies, prostate cancer, others.

In each centre, data collection will be performed in pre-identified outpatient clinics and inpatient wards. Participation in the study will be offered to eligible patients until the pre-defined sample size is reached.

All patients in the sample will fill in the EUonQoL-Kit. Additionally, three subgroups of patients will be proposed to fill in the following additional questionnaires:

  • EORTC QLQ-C30, to evaluate concurrent validity ("concurrent validity" sub-sample: 10% of the overall sample, stratified for the three disease conditions: A, B, and C).
  • Live CAT version of the EUonQoL-Kit, to test the feasibility of such implementation ("live CAT" sub-sample: 10% of the overall sample, stratified for the three disease conditions).
  • EUonQoL-Kit, a second time, (2-7 days after the first administration), to assess test-retest reliability ("test-retest" sub-sample: 10% of the overall sample, stratified for the three disease conditions).

The development of the EUonQoL-Kit has involved multiple stakeholder groups, also including patients, through different steps:

  • Systematic search, collection, and analysis of existing validated QoL tools, metrics, item banks in databases to identify QoL dimensions not adequately covered by existing tools.
  • A mixed-method study including patient interviews, a Delphi survey with patients and healthcare providers, aimed at collecting patient priorities and preferences on QoL dimensions, followed by a usability testing of a preliminary version of the EUonQoL-Kit.
  • Development of the EUonQoL-Kit, including three static questionnaires specifically developed for patients in active treatment, survivors and in palliative care, and three dynamic versions of the same questionnaires. The final version of the six questionnaires will be submitted as an amendment to the current protocol when available.
  • Translation and cultural adaptation of the EUonQoL-Kit across European countries.

The CAT version of the EUonQoL-Kit requires an item bank containing IRT-calibrated items (questions) and an algorithm for selecting the most relevant item to ask, based on the previous answers. Such dynamic system ensures that each patient is asked the most relevant and informative items.

CAT/IRT-based technology will be implemented as:

  • Short forms within the EUonQoL-Kit static version. Three static versions will be designed to secure the optimal fit between items and patient groups.
  • Live CAT, within the EUonQoL-Kit dynamic version. Each item is selected based on the previous answers, while the patient completes the questionnaire.

The final EUonQoL-kit will include both traditional and CAT/IRT-based items.

The overall sample size is planned to be 4,600 patients. Expecting a lower recruitment rate of 10-15%, at least 4,000 patients will be enrolled, a number suitable for data analyses.

Scientifically sound recommendations on statistical power/sample size in validation studies are lacking and minimum rule-of-thumb requirements are provided. The highest number of participants recommended for exploratory and confirmatory factor analyses (EFA & CFA) is 1,000; thus, the sample size by subgroup mentioned above is appropriate to evaluate construct validity.

Analyses of the primary aim will include:

  • EFA & CFA to assess structural validity. The sample will be divided into two random sub-samples, stratified by disease stage and country. The first sub-sample will be used to perform EFA, and the model obtained will be confirmed by CFA in the second sub-sample. Goodness-of-fit will be measured by the Root Mean Square Error of Approximation, Comparative Fit Index, and Tucker-Lewis Index.
  • Distribution of scale scores, examined by calculating the observed range, floor and ceiling effects, and statistics of central tendency and dispersion.
  • Reliability in terms of internal consistency (estimated with Cronbach's alpha coefficient of multi-item scales) and reproducibility (agreement between the two administrations of EUonQoL-Kit estimated with the Intra-class Correlation Coefficient).
  • Concurrent validity, assessed by the multi-trait multimethod matrix between the EUonQoL-Kit and the EORTC-QLQ-C30 questionnaire.
  • Construct validity based on hypotheses-testing, assessed through the patterns of EUonQoL-Kit scores across known groups defined by variables such as disease stage, treatment, and Eastern Cooperative Oncology Group performance status. Mean differences among groups will be tested with ANOVA, and the magnitude of the difference between them will be estimated by Effect Size coefficient: > 0.8 high, 0.5 moderate, and 0.2 low.
  • Test of Differential Item Functioning, used to assess item equivalence.

Analyses of the secondary aims will include:

  • Assessment of acceptability and respondent burden, based on the response rate and percentage of missing items, as well as the time needed to complete the questionnaire.
  • Validation of the CAT version of the EUonQoL-Kit, performed by 1) comparing scores obtained with the static and dynamic versions to test if they produce interchangeable results; and 2) assessing whether the items selected for the static versions should be adjusted to obtain optimal assessment.
  • To analyse QoL inequalities across clusters of populations, countries, and healthcare systems, multi-level regression models will be applied across three levels: individual, cancer centre and country. It will also be explored whether the magnitude of subgroup differences (e.g., for age or education) varies across countries.
  • Analysis of QoL disparities across different patient groups will include gender, ethnicity, religion, geographical area, psychological and socio-economic factors, and education level.

Data collected include personal information belonging to special categories, like health-related data, origins, lifestyles etc. Legal basis to collect and process information is the data subject consent, which is necessary to take part in this study. A data protection expert will assess the impact on data protection throughout the duration of the study. Patient registration and CRF data collection will be centralized through the CRF.net platform, developed and owned by Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli (INT-NA) and released with the GPL v3 license. Data will be stored by INT-NA on cloud services provided by Telecom Italia S.p.A. and located in Acilia (Italy).

Patient-reported data associated to QR codes will be collected by an ad hoc mobile app developed by Clinical Research Technology (CRT), Salerno (Italy).

The CAT version of EUonQoL-Kit will be administered through the integration of a CAT engine provided by the European Organization for Research and Treatment of Cancer (EORTC), sited in Bruxelles (Belgium).

Data processing is managed by:

  • Istituto Nazionale Tumori, IRCCS - Milan (INT): INT serves as the data controller.
  • Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli (INT-NA). INT-NA will be appointed as data processor under article 28 GDPR and will be responsible for patient enrolment, questionnaire assignment through the generation of a QR code, clinician reported data collection through the electronic Case Report Form (eCRF), management of the interface with the CAT engine and with the mobile app for the administration of EUonQoL-kit items.
  • CRT: based on a QR code provided by CRF.net platform, the mobile app administers specific QoL questionnaires for specific subgroup of patients. For each item administered, the app will directly transfer the answer to the platform, without recording/storing any content. Such a procedure avoids any possibility to link contents to patients' IDs.
  • EORTC: in case of the dynamic EUonQoL-Kit administration, EORTC CAT will be appointed as data processor under article 28 GDPR and will get access to each pseudonymized answer as provided by the CRF.net platform. The EORTC CAT will delete any content once the questionnaire has been submitted including scores sent to the CRF.net platform.

The CRF.net platform is accessible online by investigators and data managers through username and password and is protected through encrypted data certified by SSL certificates and HTTPS protocols. For each registered patient, the CRF.net platform generates a Quick Response (QR) code that will be scanned with the tablet to allow the patient to complete the questionnaires.

The interface of the platforms allows data review and cleaning in the central archive directly (with a limited and controlled access of data-managers and investigators). Each operation done in the archive database is registered through track-change.

Each participating centre will receive tablet devices from the sponsor to get access to the CRF.net platform and collect data directly from patients. Results will be shared as open data in a completely anonymous and aggregated form. After 5 years since data collection, all personal information related to the study, including informed consents, will be anonymized/destroyed according to the delay stated by the Ethics Code on data processing for statistics or scientific research purposes issued by the Italian Data Protection Authority under article 20, par. 4, LD 101/2018.

Patients could exercise their rights by submitting requests to the staff identified in the private information. All centres have appointed a data protection officer under the General Data Protection Regulation (GDPR) and an internal data breach policy.

This study was designed and shall be implemented and reported in accordance with national and European legal and ethical requirements. Moreover, the survey will follow the ethical principles laid down in the Declaration of Helsinki and the ethical principles of observational research on potentially fragile patients.

The protocol, Informative Sheet, and Informed Consent Form must be reviewed and approved by ethics committees of each centre involved. No study procedure can be performed before the written informed consent has been provided.

Study Type

Observational

Enrollment (Estimated)

4000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Albania
      • Tirana, Albania, 1000
        • Mother Teresa University Hospital
  • Austria
      • Vienna, Austria, 10090
        • Comprehensive Cancer Center
  • Belgium
      • Kortrijk, Belgium, 8500
        • Kortrijk Kankercentrum AZ Groeninge
  • Bulgaria
      • Varna, Bulgaria, 9000
        • Bulgarian Joint Cancer Network
        • Contact:
          • Ivaylo Petrov, Mr
  • Croatia
      • Zagreb, Croatia, 10000
        • Klinika za tumore Klinički bolnički centar Sestre milosrdnice
  • Cyprus
      • Nicosia, Cyprus, 2000
        • Cyprus Association of Cancer Patients and Friends (PASYKAF)
        • Contact:
          • Maria Krini, Ms
  • Czechia
      • Brno, Czechia, 60200
        • Masarykuv onkologicky ustav
  • Denmark
      • Hillerød, Denmark, 3400
        • Region Hovedstaden (Rigshospitalet)
        • Contact:
          • Helle Pappot, Prof
  • Estonia
      • Tallinn, Estonia, 13419
        • North Estonia Medical Centre
        • Contact:
          • Vahur Valvere, Dr
      • Tartu, Estonia, 50406
        • Sihtasutus Tartu Ülikooli Kliinikum
  • Finland
      • Helsinki, Finland, 00290
        • HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala
  • France
      • Angers, France, 49055
        • lnstitut de Cancérologie de l'Ouest (ICO)
        • Contact:
          • Robert Marie, DR
      • Paris, France, 75005
        • Institut Curie
        • Contact:
          • Anne Brédart, Dr
      • Villejuif, France, 94805
        • Gustave Roussy
        • Contact:
          • Maria A Franzoi, Dr
  • Georgia
      • Tbilisi, Georgia, 0144
        • Petre Shotadze Tbilisi Medical Academy
        • Contact:
          • Ekaterina Kldiashvili, Prof
  • Germany
      • Frankfurt, Germany, 60590
        • Universitäres Centrum für Tumorerkrankungen (UCT)
      • Heidelberg, Germany, 69120
        • Deutsches Krebsforschungszentrum (DKFZ)
        • Contact:
          • Volker Arndt, Prof
      • Munich, Germany, 81377
        • Comprehensive Cancer Center Munich
        • Contact:
          • Theres Fey, Dr
  • Greece
      • Athens, Greece, 11522
        • General Oncology Hospital of Athens - Saint Savvas
  • Hungary
      • Budapest, Hungary, 1122
        • Orszagos Onkologiai Intezet
        • Contact:
          • Orsolya Horvath, Dr
  • Ireland
      • Dublin, Ireland, D08 NHY1
        • Trinity St. James's Cancer Institute
  • Italy
      • Bari, Italy
        • Istituto Tumori Giovanni Paolo II, IRCCS
        • Contact:
          • Alessandro Rizzo, Dr
      • Milan, Italy
      • Milan, Italy, 20121
        • Istituto Europeo di Oncologia, IRCCS
        • Contact:
          • Gabriella Pravettoni, Prof
      • Roma, Italy, 00144
        • Istituto Nazionale Tumori Regina Elena
  • Latvia
      • Riga, Latvia, LV-1038
        • Riga East University Hospital
  • Lithuania
      • Vilnius, Lithuania, 08406
        • National Cancer Institute
        • Contact:
          • Audrius Dulskas, Dr
  • Moldova, Republic of
      • Chisinau, Moldova, Republic of, MD-2025
        • Oncologic Institute of Moldova
        • Contact:
          • Vadim Pagonet, DR
  • Netherlands
      • Amsterdam, Netherlands, 1066 CX
        • Netherlands Cancer Institute
        • Contact:
          • Lonneke van de Poll, Prof
  • Norway
      • Oslo, Norway, 0450
        • Oslo University Hospital (OUS)
        • Contact:
          • Marianne Grønlie Guren, Prof
  • Poland
      • Poznań, Poland, 61-866
        • Greater Poland Cancer Centre
        • Contact:
          • Maria Litwiniuk, Prof
      • Warsaw, Poland, 02-781
        • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy
        • Contact:
          • Iwona Lugowska
  • Portugal
      • Porto, Portugal, 4200-072
        • Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO-Porto)
  • Romania
      • Bucharest, Romania, 022328
        • Institutul Oncologic "Al. Trestioreanu" (IOB)
      • Cluj-Napoca, Romania, 400015
        • The "Prof. Dr. Ion Chiricuta"Institute of Oncology (IOCN)
        • Contact:
          • Tudor Ciuleanu, Prof
  • Serbia
      • Sremska Kamenica, Serbia, 21204
        • Oncology Institute of Vojvodina
        • Contact:
          • Milana Mitric Askovic, Dr
  • Slovakia
      • Bratislava, Slovakia, 83310
        • National Cancer Institute (Národný onkologický ústav)
        • Contact:
          • Michal Chovanec, Prof
  • Slovenia
      • Ljubljana, Slovenia, 1000
        • Onkološki Inštitut Ljubljana
  • Spain
      • Barcelona, Spain, 08035
        • Vall Hebron Institute of Oncology (VHIO)
        • Contact:
          • Maria Vieito, Dr
      • Madrid, Spain, 28040
        • Fundacion Jimenez Diaz University Hospital
      • Valence, Spain, 46009
        • Fundacion Instituto Valenciano de Oncologia (IVO)
  • Sweden
      • Gothenburg, Sweden, 413 45
        • Sahlgrenska comprehensive cancer centre
  • Turkey
      • Gebze, Turkey, 41400
        • Anadolu Medical Center
      • Istanbul, Turkey, 34718
        • Turkey Cancer Institute
        • Contact:
          • Mahmut Gumus, Prof
  • United Kingdom
      • Leeds, United Kingdom, LS1 3EX
        • Leeds Teaching Hospitals NHS Trust
        • Contact:
          • Alexandra Gilbert, Dr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients in one of the following three conditions will be screened for their eligibility:

A) In active treatment: Undergoing or recently completed curative treatment for early-stage cancers OR undergoing or recently completed non-curative treatment for ad-vanced or metastatic cancers, including disease controlling/life prolonging tumour-directed treatment.

B) Survivors: Being disease-free without evidence of active cancer, and at least one year off active treatment (with the exception of long-term adjuvant hormonotherapy).

C) Palliative Care (PC): patients with advanced cancers with projected prognosis <12 months and ECOG ≥2 OR referred to a specialist palliative care team for symptom control.

OR receiving non-curative systemic treatment or radiotherapy purely for symptom control.

Description

Inclusion Criteria:

  • Age 18 years or more.
  • Present or past histologically confirmed diagnosis of solid tumour or haematological malignancy.
  • Being in one of these three conditions: A) Patients in active treatment; B) Survivors; C) in Palliative Care.
  • Native tongue or fluent in the language of the questionnaire
  • Written informed consent to the study.

Exclusion Criteria:

  • Cognitive impairment preventing the completion of the questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
A) EUonQoL-Kit - Active Treatment module
EUonQoL-Kit questionnaire specifically designed and administered to patients undergoing/having recently completed curative treatment for early-stage cancers OR undergoing/having recently completed non-curative treatment for advanced or metastatic cancers, including disease controlling/life prolonging tumour-directed treatment.
Other: Administration of the EUonQoL-Kit - Active Treatment questionnaire
Electronic questionnaire to be administered to patients in active treatment.
B) EUonQoL-Kit - Survivors module
EUonQoL-Kit questionnaire specifically designed and administered to people being disease-free without evidence of active cancer, and at least one year off active treatment (with the exception of long-term adjuvant hormonotherapy).
Other: Administration of the EUonQoL-Kit - Survivors questionnaire
Electronic questionnaire to be administered to cancer survivors.
C) EUonQoL-Kit - Palliative Care module
EUonQoL-Kit questionnaire specifically designed and administered to patients with advanced cancers with projected prognosis <12 months and Eastern Cooperative Oncology Group (ECOG) ≥2 OR referred to a specialist palliative care team for symptom control, OR receiving non-curative systemic treatment or radiotherapy purely for symptom control.
Other: Administration of the EUonQoL-Kit - Palliative Care questionnaire
Electronic questionnaire to be administered to patients in palliative care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Validity and reliability of the EUonQoL-Kit static version
Time Frame: All assessments at time of administration of the questionnaires, apart reproducibility that will be assessed with a re-test after 7 days (± 1) for patients in active treatments and survivors, and after 2 days (± 1) for patients in palliative care
Exploratory and confirmatory factor analyses, distribution of the scales' scores, reliability in terms of internal consistency and reproducibility, concurrent and construct validity, differential item functioning.
All assessments at time of administration of the questionnaires, apart reproducibility that will be assessed with a re-test after 7 days (± 1) for patients in active treatments and survivors, and after 2 days (± 1) for patients in palliative care

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability of the EUonQoL-Kit
Time Frame: At day 1
Acceptability of the EUonQoL-Kit and reasons for refusal, including patient burden in filling in the questionnaire
At day 1
Validation of the EUonQoL-Kit dynamic (CAT) version
Time Frame: At day 1
Comparison of the scores obtained with the static and dynamic versions to test if they produce similar, interchangeable results; assessment to test whether the items selected for the static version and the related CAT-settings should be adjusted to obtain optimal assessment.
At day 1
Assessment of Quality of Life (QoL) inequalities across clusters of European populations, countries, and healthcare systems, using EUonQoL-Kit questionnaires
Time Frame: At day 1
Analysis of the QoL scores (dependent variable) according to individual-level variables as well as country/health system level variables (independent variables)
At day 1
Socio-demographic and clinical factors potentially associated with QoL
Time Frame: At day 1
Assessment of QoL disparities across different patient groups (by gender, ethnicity, religion, area, psychological and socio-economic factors, and education level)
At day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Collaborators

The Leeds Teaching Hospitals NHS Trust
University of Leeds
European Organisation for Research and Treatment of Cancer - EORTC
Medical University Innsbruck
The Netherlands Cancer Institute
UNICANCER
Gustave Roussy, Cancer Campus, Grand Paris
University of Milan
Institut Curie
Istituto Europeo di Oncologia
Istituti Fisioterapici Ospitalieri
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Alleanza Contro il Cancro
Oslo universitetssykehus HF
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (German Cancer Research Center)
Hospital del Mar Research Institute
EAPC
EUROPEAN CANCER ORGANISATION
DIGICORE/IFO
STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG
SporeData OÜ
ORGANISATION OF EUROPEAN CANCER INSTITUTES
FEDERAZIONE ITALIANA DELLE ASSOCIAZIONI DI VOLONTARIATO IN ONCOLOGIA
SDRUZHENIE ASOTSIATSIA NA PATSIENTITE SONKOLOGICHNI ZABOLYAVANIA I PRIYATELI
FEDERATIA ASOCIATIILOR BOLNAVILOR DE CANCER
Region Hovedstaden (Bispebjerg Hospital & Rigshospitalet)

Investigators

  • Principal Investigator: Cinzia Brunelli, PhD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2024

Primary Completion (Estimated)

October 31, 2024

Study Completion (Estimated)

October 31, 2024

Study Registration Dates

First Submitted

June 28, 2023

First Submitted That Met QC Criteria

July 7, 2023

First Posted (Actual)

July 17, 2023

Study Record Updates

Last Update Posted (Actual)

July 19, 2023

Last Update Submitted That Met QC Criteria

July 17, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • INT 106/23

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Administration of the EUonQoL-Kit - Active Treatment questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe